Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.
AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, despite keeping its options open. | AstraZeneca is showing no signs of ...
By Andrew MacAskill LONDON, Jan 26 (Reuters) - UK-headquartered pharmaceutical firm AstraZeneca's CEO Pascal Soriot will join Prime Minister Keir Starmer's trip to China this week, said a source ...
Key Insights Using the 2 Stage Free Cash Flow to Equity, AstraZeneca fair value estimate is UK£250 AstraZeneca's ...
AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...
AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. Pfizer CEO Albert Bourla appeared with ...
The AstraZeneca share price has risen to all-time highs over the past 12 months. Dr James Fox wishes he had more of the ...
Saturday through Tuesday: WEATHER ALERT for more dangerous cold and significant snowfall.Highs reach the low 20s Saturday and Sunday with wind chills in the sin Marylanders rush to stock up, leaving ...
Only 40% of new medicines are currently available in Europe, compared with 85% in the United States. AstraZeneca executive, Ruud Dobber highlights the need for higher GDP spending on innovation and ...
AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results